This report details the experience of a 66-year-old woman who started secukinumab therapy for new-onset erythrodermic psoriasis. Shortly after beginning treatment, she developed a serious condition called systemic capillary leak syndrome, which involved high fever, difficulty breathing, swelling, and large amounts of fluid in her lungs. Her skin also became very red and inflamed. After the medication was stopped, her fever went away, the fluid in her lungs decreased, and her skin redness improved.
The patient was hospitalized for these severe symptoms. The report notes that the woman had acute erythroderma and systemic capillary leak syndrome as adverse events. While her condition improved after discontinuing the drug, the study does not provide enough data to confirm that secukinumab directly caused the syndrome. The authors state that a potential link between the drug administration and disease progression requires further investigation.
Readers should understand that this is a single case report, meaning it involves only one person. Such small studies cannot prove cause and effect or show how common this reaction might be. Clinicians managing severe psoriasis should remain vigilant for signs of systemic capillary leak syndrome, especially in patients with acute erythroderma. Careful consideration is needed when choosing biologic agents for high-risk patients until more evidence is available.